### IN THIS ISSUE
Highlighted research articles .......................... 327

### NEWS IN BRIEF
Important news stories affecting the community .......... 332

### NEWS IN DEPTH
Q&A: Olufunmilayo Olopade on Genomics and Breast Cancer .......................... 335

China Biotech Scene, U.S. Collaborations Grow ...... 336

### RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature .............. 337

### ONLINE
For more News and Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

### VIEWS
In The Spotlight
Unraveling the Architecture of Classic Hodgkin Lymphoma One Cell at a Time .......................... 342
D.A.C. Fisher and S.T. Oh
See article, p. 406

Regulatory T Cells Keep Pancreatic Cancer at Bay ...................... 345
B. Aykut, R. Chen, and G. Miller
See article, p. 422

TBK1 Activation by VHL Loss in Renal Cell Carcinoma: A Novel HIF-Independent Vulnerability .... 348
Z. Bakouny and D.A. Barbie
See article, p. 460

### REVIEW
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy ......................... 351
J. Chou, D.A. Quigley, T.M. Robinson, F.Y. Feng, and A. Ashworth

### RESEARCH BRIEFS
Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment .................. 371

Précis: The circadian-rhythm protein CLOCK was implicated in increasing stem-like properties of glioblastoma cells and promoting infiltration of immunosuppressive microglia in the tumor microenvironment.

Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell–Mediated Tumor Killing .................. 382

Précis: UBA7, encoded by an interferon-stimulated gene (ISG), suppressed tumor growth in mouse models of breast cancer via covalently conjugating the protein ISG15 to other ISG products, including STAT1/2, to mediate an antitumor immune response.

### RESEARCH ARTICLES
Acchlorbutin plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia .................. 394

Précis: In a phase IIB/II clinical trial, the combination of obinutuzumab with the BTK inhibitor acchlorbutin was effective and tolerable in patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.


Précis: Single-cell RNA sequencing, immunohistochemistry, and imaging mass cytometry identified immunosuppressive LAG3+ T cells near malignant cells in the MHC class II− classic Hodgkin lymphoma microenvironment.

See commentary, p. 342

Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis ................. 422


Précis: Contrary to prior results, Treg depletion in mouse models of pancreatic ductal adenocarcinoma sped carcinogenesis by altering the fibroblast and myeloid-cell populations in the tumor microenvironment.

See commentary, p. 345

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma ........ 440


Précis: The epigenetic and transcriptional effects of CREBBP hotspot mutations in diffuse large B-cell lymphoma (DLBCL) were reversed by HDAC3 inhibition, which synergized with PD-L1 blockade in a mouse model of DLBCL.

Correction

Correction: Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy ....................... 476

Cancer-cell stemness is associated with immunosuppression and poor prognosis in glioblastoma and many other malignancies. Chen and colleagues found that depletion of the circadian-rhythm gene CLOCK in glioma stem cells (GSC) led to reduced self-renewal capabilities and decreased markers of immunosuppressive microglia infiltration. Mechanistically, CLOCK-depleted cells had reduced levels of OLFML3, encoding a secreted protein involved in intercellular interactions. In mouse models, tumors derived from CLOCK-depleted GSCs were less aggressive than those derived from control GSCs, leading to increased survival in mice bearing CLOCK-depleted tumors, and exhibited reduced signs of stemness and microglia infiltration. Bolstering the proposed mechanism, tumors derived from OLFML3-depleted GSCs were also less aggressive than controls. For details, please see the article by Chen and colleagues on page 371.